MYOS RENS Technology Inc. (NASDAQ:MYOS) releases financial results for the three and nine months ended September 30, 2019

On Thursday MYOS RENS Technology Inc. (NASDAQ:MYOS) traded with change of -2.5% on volume of 11876 shares in the last session as compared to average volume of 4772 shares. During last trade its minimum price was $1.56 and it gained highest price of $1.62. MYOS has total market capitalization of $14306759. Its closing value stands at $1.56.

On Nov. 7, 2019, MYOS RENS Technology Inc. (NASDAQ:MYOS) an advanced nutrition company and the owner of Fortetropin®, an innovative proprietary bioactive composition made from fertilized egg yolks that helps build lean muscle, declared its financial results for the three and nine months ended September 30, 2019.

Financial Highlights: (Amounts in thousands except where noted)

Third Quarter – Three Months Ended September 30, 2019:

  • Net revenues increased $284, or 430%, to $350 compared to net revenues of $66 for the three months ended September 30, 2018.
  • Gross profit for the three months ended September 30, 2019 increased $169 or 2,414% to $176, compared to $7 for the three months ended September 30, 2018.
  • Operating expenses for the three months ended September 30, 2019 increased $171 or 18% to $1,087 compared to $916 for the three months ended September 30, 2018.
  • Net loss increased $10 or 1% to $921 for the three months ended September 30, 2019 compared to $911 for the three months ended September 30, 2018.

Leave a Reply

Your email address will not be published. Required fields are marked *